NCT06164873

A Study of IBI362 9 mg in Chinese Adults With Obesity

A Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of IBI362 9 mg in Chinese Participants With Obesity (GLORY-2)

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 462 (actual)
• Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study evaluating the efficacy and safety of IBI362 9 mg in obese subjects. Subjects will be randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a 60-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	IBI362	Once-weekly injections of gradually increased doses of IBI362
DRUG	Placebo	Once-weekly injections of volume-matched placebo

Timeline

• Start date: 2023-12-27
• Primary completion: 2025-06-27
• Completion: 2025-09-19
• First posted: 2023-12-11
• Last updated: 2024-08-27

Locations

1 site across 1 country: China